Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors within the central anxious system, conolidine modulates alternate molecular targets. A Science Developments research identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://hillaryg515ucf9.wssblogs.com/profile